Thymosin Alpha-1
Also known as Ta1
Thymic 28-amino-acid immunomodulator
A thymus-derived peptide studied for T cell maturation and immune response in infection and vaccine research.
How it works
Signals through toll-like receptors on dendritic cells, promoting T helper 1 differentiation and improved antigen presentation.
What research has shown
Sepsis and hepatitis trials report improved immune markers and, in some sepsis cohorts, reduced mortality signals.
Reported ranges in the literature
Low end
0.8 mg twice weekly
Optimal
1.6 mg twice weekly, the common trial dose
High end
3.2 mg twice weekly in intensive protocols
Frequency reported in the literature: Two to seven times weekly depending on protocol
Protocol duration and pairing
Typical study duration
4 to 24 weeks; hepatitis and immune protocols run longest.
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.